Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers

Hankui Chen, Helu Liu, Hanqing Zou, Rui Chen, Yuhong Dou, Shile Sheng, Shengming Dai, Junmei Ai, Joshua Melson, Rick A. Kittles, Mehdi Pirooznia, Michael J. Liptay, Jeffrey A. Borgia, Youping Deng

Research output: Contribution to journalArticle

Abstract

Stable blood based miRNA species have allowed for the differentiation of patients with various types of cancer. Therefore, specific blood-based miRNA might be considered as a methodology which could be informative of the presence of cancer potentially from multiple distinct organ sites. Recently, miR-21 has been identified as an "oncomir" in various tumors while miR-152 as a tumor suppressor. In this study, we investigated whether circulating miR-21 and miR-152 can be used for early detection of lung cancer (LuCa), colorectal carcinoma (CRC), breast cancer (BrCa) and prostate cancer (PCa), with distinguishing cancer from various benign lesions on these organ sites. We measured the two miRNA levels by using real-time RT-PCR in plasma samples from a total of 204 cancer patients, 159 various benign lesions, and 228 normal subjects. We observed significantly elevated expression of miR-21 and miR-152 in LuCa, CRC, and BrCa when compared with normal controls. We also found upregulation of plasma miR-21 and miR-152 levels in patients with benign lesions of lung and breast, as compared to normal controls, respectively. No significant expression variation of the two miRNAs was observed in PCa or prostatic benign lesions as compared to healthy controls. Receiver operating characteristic (ROC) analyses revealed that miR-21 and/or miR-152 can discriminate LuCa, CRC and BrCa from normal controls. Our results suggest that plasma miR-21 and miR-152 may serve as non-specific noninvasive biomarkers for early screening of LuCa, CRC, and BrCa, but not PCa.

Original languageEnglish (US)
Pages (from-to)490-499
Number of pages10
JournalJournal of Cancer
Volume7
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Colorectal Neoplasms
Biomarkers
Prostatic Neoplasms
MicroRNAs
Lung Neoplasms
Neoplasms
Breast Neoplasms
Early Detection of Cancer
ROC Curve
Real-Time Polymerase Chain Reaction
Breast
Up-Regulation
Lung

Keywords

  • Cancer
  • miRNA

ASJC Scopus subject areas

  • Oncology

Cite this

Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers. / Chen, Hankui; Liu, Helu; Zou, Hanqing; Chen, Rui; Dou, Yuhong; Sheng, Shile; Dai, Shengming; Ai, Junmei; Melson, Joshua; Kittles, Rick A.; Pirooznia, Mehdi; Liptay, Michael J.; Borgia, Jeffrey A.; Deng, Youping.

In: Journal of Cancer, Vol. 7, No. 5, 2016, p. 490-499.

Research output: Contribution to journalArticle

Chen, H, Liu, H, Zou, H, Chen, R, Dou, Y, Sheng, S, Dai, S, Ai, J, Melson, J, Kittles, RA, Pirooznia, M, Liptay, MJ, Borgia, JA & Deng, Y 2016, 'Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers', Journal of Cancer, vol. 7, no. 5, pp. 490-499. https://doi.org/10.7150/jca.12351
Chen, Hankui ; Liu, Helu ; Zou, Hanqing ; Chen, Rui ; Dou, Yuhong ; Sheng, Shile ; Dai, Shengming ; Ai, Junmei ; Melson, Joshua ; Kittles, Rick A. ; Pirooznia, Mehdi ; Liptay, Michael J. ; Borgia, Jeffrey A. ; Deng, Youping. / Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers. In: Journal of Cancer. 2016 ; Vol. 7, No. 5. pp. 490-499.
@article{181a11b81304425b9b1e1b16b78acdb6,
title = "Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers",
abstract = "Stable blood based miRNA species have allowed for the differentiation of patients with various types of cancer. Therefore, specific blood-based miRNA might be considered as a methodology which could be informative of the presence of cancer potentially from multiple distinct organ sites. Recently, miR-21 has been identified as an {"}oncomir{"} in various tumors while miR-152 as a tumor suppressor. In this study, we investigated whether circulating miR-21 and miR-152 can be used for early detection of lung cancer (LuCa), colorectal carcinoma (CRC), breast cancer (BrCa) and prostate cancer (PCa), with distinguishing cancer from various benign lesions on these organ sites. We measured the two miRNA levels by using real-time RT-PCR in plasma samples from a total of 204 cancer patients, 159 various benign lesions, and 228 normal subjects. We observed significantly elevated expression of miR-21 and miR-152 in LuCa, CRC, and BrCa when compared with normal controls. We also found upregulation of plasma miR-21 and miR-152 levels in patients with benign lesions of lung and breast, as compared to normal controls, respectively. No significant expression variation of the two miRNAs was observed in PCa or prostatic benign lesions as compared to healthy controls. Receiver operating characteristic (ROC) analyses revealed that miR-21 and/or miR-152 can discriminate LuCa, CRC and BrCa from normal controls. Our results suggest that plasma miR-21 and miR-152 may serve as non-specific noninvasive biomarkers for early screening of LuCa, CRC, and BrCa, but not PCa.",
keywords = "Cancer, miRNA",
author = "Hankui Chen and Helu Liu and Hanqing Zou and Rui Chen and Yuhong Dou and Shile Sheng and Shengming Dai and Junmei Ai and Joshua Melson and Kittles, {Rick A.} and Mehdi Pirooznia and Liptay, {Michael J.} and Borgia, {Jeffrey A.} and Youping Deng",
year = "2016",
doi = "10.7150/jca.12351",
language = "English (US)",
volume = "7",
pages = "490--499",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "5",

}

TY - JOUR

T1 - Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers

AU - Chen, Hankui

AU - Liu, Helu

AU - Zou, Hanqing

AU - Chen, Rui

AU - Dou, Yuhong

AU - Sheng, Shile

AU - Dai, Shengming

AU - Ai, Junmei

AU - Melson, Joshua

AU - Kittles, Rick A.

AU - Pirooznia, Mehdi

AU - Liptay, Michael J.

AU - Borgia, Jeffrey A.

AU - Deng, Youping

PY - 2016

Y1 - 2016

N2 - Stable blood based miRNA species have allowed for the differentiation of patients with various types of cancer. Therefore, specific blood-based miRNA might be considered as a methodology which could be informative of the presence of cancer potentially from multiple distinct organ sites. Recently, miR-21 has been identified as an "oncomir" in various tumors while miR-152 as a tumor suppressor. In this study, we investigated whether circulating miR-21 and miR-152 can be used for early detection of lung cancer (LuCa), colorectal carcinoma (CRC), breast cancer (BrCa) and prostate cancer (PCa), with distinguishing cancer from various benign lesions on these organ sites. We measured the two miRNA levels by using real-time RT-PCR in plasma samples from a total of 204 cancer patients, 159 various benign lesions, and 228 normal subjects. We observed significantly elevated expression of miR-21 and miR-152 in LuCa, CRC, and BrCa when compared with normal controls. We also found upregulation of plasma miR-21 and miR-152 levels in patients with benign lesions of lung and breast, as compared to normal controls, respectively. No significant expression variation of the two miRNAs was observed in PCa or prostatic benign lesions as compared to healthy controls. Receiver operating characteristic (ROC) analyses revealed that miR-21 and/or miR-152 can discriminate LuCa, CRC and BrCa from normal controls. Our results suggest that plasma miR-21 and miR-152 may serve as non-specific noninvasive biomarkers for early screening of LuCa, CRC, and BrCa, but not PCa.

AB - Stable blood based miRNA species have allowed for the differentiation of patients with various types of cancer. Therefore, specific blood-based miRNA might be considered as a methodology which could be informative of the presence of cancer potentially from multiple distinct organ sites. Recently, miR-21 has been identified as an "oncomir" in various tumors while miR-152 as a tumor suppressor. In this study, we investigated whether circulating miR-21 and miR-152 can be used for early detection of lung cancer (LuCa), colorectal carcinoma (CRC), breast cancer (BrCa) and prostate cancer (PCa), with distinguishing cancer from various benign lesions on these organ sites. We measured the two miRNA levels by using real-time RT-PCR in plasma samples from a total of 204 cancer patients, 159 various benign lesions, and 228 normal subjects. We observed significantly elevated expression of miR-21 and miR-152 in LuCa, CRC, and BrCa when compared with normal controls. We also found upregulation of plasma miR-21 and miR-152 levels in patients with benign lesions of lung and breast, as compared to normal controls, respectively. No significant expression variation of the two miRNAs was observed in PCa or prostatic benign lesions as compared to healthy controls. Receiver operating characteristic (ROC) analyses revealed that miR-21 and/or miR-152 can discriminate LuCa, CRC and BrCa from normal controls. Our results suggest that plasma miR-21 and miR-152 may serve as non-specific noninvasive biomarkers for early screening of LuCa, CRC, and BrCa, but not PCa.

KW - Cancer

KW - miRNA

UR - http://www.scopus.com/inward/record.url?scp=84971539120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971539120&partnerID=8YFLogxK

U2 - 10.7150/jca.12351

DO - 10.7150/jca.12351

M3 - Article

VL - 7

SP - 490

EP - 499

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 5

ER -